Prevalence of depression, quality of life and antidepressant treatment in the Danish General Suburban Population Study

Abstract

Background: The Danish General Suburban Population Study (GESUS), the objective of which is to facilitate epidemiological and genetic research, has included the Major Depression Inventory (MDI) and the WHO-Five Well-Being Index (WHO-5) among the medical health questionnaires. We were thus in a position to compare the 2-week prevalence of ICD-10 depression in the period from 2010 to 2012 with our previous Danish general population study from 2003, in which the MDI was also included. Aims: The aim of our analysis was not only to evaluate the point prevalence of ICD-10 depression but also to describe the prevalence of antidepressants received by the respondents in the GESUS study and the correspondence to their subjective well-being on the WHO-5 questionnaire. Methods: To evaluate the validity (scalability) of the MDI and the WHO-5 in the GESUS study we performed the non-parametric Mokken analysis. The scalability of the MDI and the WHO-5 was quite acceptable. Results: In total, 14,787 respondents were available from a response rate of 50%. The 2-week prevalence of ICD-10 depression was 2.3%, which is rather similar to the 2.8% in our 2003 study. The rate of people receiving antidepressants increased consistently with increasing severity of ICD-10 depression. Conclusion: This study has confirmed that the use of the MDI to obtain an ICD-10 depression diagnosis gives rather conservative estimates of the 2-week prevalence of depression in the Danish general population. The prescription of antidepressants depends on the severity of the ICD-10 depression diagnosis.

• Depressive illness
• Major Depression Inventory
• WHO-5

Acknowledgements

The GESUS study received support from Johan and Lise Boserup Foundation; TrygFonden; Det Kommunale Momsfond; Johannes Fog's Foundation; Region Zealand; Region Zealand Foundation; Naestved Hospital; Naestved Hospital Foundation; the National Board of Health; Danish Agency for Science, Technology and Innovation.

Disclosure of interest: Kaj Sparle Christensen and Mogens Vestergaard are supported in part by an unrestricted grant from the Lundbeck Foundation. Christina Ellervik, Jan Kvetny and Per Bech have none to disclose.